A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Phase of Trial: Phase II/III
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 28 Nov 2016 Status changed from recruiting to suspended.
- 22 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.